文献速递神经肿瘤

IDH突变胶质瘤中肿瘤分级、年龄、强化程度和切除范围的生物学意义:在IDH抑制剂时代应如何指导治疗决策?

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
PubMed 文献 · Neuro Oncol · 2024-01-01

2016年和2021年世界卫生组织中枢神经系统肿瘤分类显著改进了IDH突变胶质瘤的分类。许多患者经更有效治疗获得长期生存,但治疗指南常仍基于包含IDH野生型和突变型患者的历史系列,通常根据术后残留肿瘤和年龄超过40岁为所谓高风险患者推荐放化疗。更近期的研究更好地揭示了与IDH突变胶质瘤患者结局相关的临床、影像和分子因素,这些认识应被用于风险分层和治疗决策。对于许多IDH突变2级和3级胶质瘤患者,在严密监测下推迟放化疗是安全的,不会危及患者总体结局。INDIGO试验显示患者从IDH抑制剂vorasidenib中获益,相当规模的人群中在推荐放化疗(其迟发不良事件影响生存质量)之前尝试此类药物似乎是合理的。正在进行的试验应有助于进一步识别从中获益的患者。

要点

  • IDH突变2级和3级胶质瘤患者中,严密监测下推迟放化疗是安全的,不会危及总体结局。
  • INDIGO试验显示IDH抑制剂vorasidenib使患者获益,在推荐放化疗前尝试此类药物对相当规模人群似乎是合理的。
  • 治疗指南常仍基于包含IDH野生型和突变型患者的历史系列,需用更近期研究认识进行风险分层和治疗决策。

核心结论

  • 对于许多IDH突变2级和3级胶质瘤患者,在严密监测下推迟放化疗是安全的,不会危及患者总体结局。
  • INDIGO试验显示患者从IDH抑制剂vorasidenib中获益,在推荐放化疗之前尝试此类药物对相当规模人群似乎是合理的。
  • 正在进行的试验应有助于进一步识别从该治疗中获益的患者。

研究设计与样本

  • 本文为综述,基于2016年和2021年世界卫生组织中枢神经系统肿瘤分类及更近期研究,讨论IDH突变胶质瘤的风险分层和治疗决策。

主要发现

  • 2016年和2021年世界卫生组织中枢神经系统肿瘤分类显著改进了IDH突变胶质瘤的分类。
  • 许多患者经更有效治疗获得长期生存,但治疗指南常仍基于包含IDH野生型和IDH突变型患者的历史系列。
  • 指南通常根据术后残留肿瘤和年龄超过40岁为所谓高风险患者推荐放疗和化疗。
  • 更近期研究更好地揭示了与IDH突变胶质瘤患者结局相关的临床、影像和分子因素。
  • INDIGO试验显示患者从IDH抑制剂vorasidenib中获益。

关键数值与推荐

  • 指南通常根据术后残留肿瘤和年龄超过40岁为所谓高风险患者推荐放疗和化疗。

临床怎么用

  • 对于许多IDH突变2级和3级胶质瘤患者,在严密监测下推迟放化疗是安全的,不会危及患者总体结局。
  • 鉴于INDIGO试验显示患者从IDH抑制剂vorasidenib中获益,对相当规模人群在推荐放化疗之前尝试此类药物似乎是合理的。

局限性

  • 治疗指南常仍基于包含IDH野生型和IDH突变型患者的历史系列。
  • 正在进行的试验应有助于进一步识别从该治疗中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments many patients experience prolonged survival. However, treatment guidelines are often still based on information from historical series comprising both patients with IDH wild-type and IDH-mutant tumors. They provide recommendations for radiotherapy and chemotherapy for so-called high-risk patients, usually based on residual tumor after surgery and age over 40. More up-to-date studies give a better insight into clinical, radiological, and molecular factors associated with the outcome of patients with IDH-mutant glioma. These insights should be used today for risk stratification and for treatment decisions. In many patients with IDH-mutant grades 2 and 3 glioma, if carefully monitored postponing radiotherapy and chemotherapy is safe, and will not jeopardize the overall outcome of patients. With the INDIGO trial showing patient benefit from the IDH inhibitor vorasidenib, there is a sizable population in which it seems reasonable to try this class of agents before recommending radio-chemotherapy with its delayed adverse event profile affecting quality of survival. Ongoing trials should help to further identify the patients that are benefiting from this treatment.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. van den Bent MJ, French PJ, Brat D, et al. The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol. 2024. PMID: 38912846. doi:10.1093/neuonc/noae107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。